Clinical perspectives for the use of new hypoxic cell sensitizers.
D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage; D004285:Dogs; D004359:Drug Therapy, Combination; D017341:Etanidazole; D006801:Humans; D008558:Melphalan / Q000008:administration & dosage; D051379:Mice; D008920:Misonidazole / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D009593:Nitroimidazoles / Q000627:therapeutic use; D010100:Oxygen; D011838:Radiation-Sensitizing Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012995:Solubility
D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D017341:Etanidazole; D008920:Misonidazole; D003520:Cyclophosphamide; D008558:Melphalan; D010100:Oxygen